


3-16-04

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 7455
In Re Application Of:    Thomas J. Staunton & Weilin Tang			
Serial No. 10/701,858	Filing Date 11/05/2003	Patent Examiner	Group Art Unit 1713
Title:  <p style="text-align: center;"><b>CURABLE COMPOSITIONS</b></p>			
<p style="text-align: center;">Address to:          Assistant Commissioner for Patents          Washington, D.C. 20231</p> <p style="text-align: center;"><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;"><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="margin-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin-left: 100px;"><b>OR</b></p> <p style="margin-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>			

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
7455

In Re Application: Thomas J. Staunton & Weilin Tang



Serial No.  
10/701,858

Filing Date  
11/05/2003

Examiner

Group Art Unit  
1713

**CURABLE COMPOSITIONS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-2025 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_

(Date)

*Signature*

*Typed or Printed Name of Person Signing Certificate*

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

*Signature of Person Mailing Correspondence*

*Typed or Printed Name of Person Mailing Certificate*

\*This certificate may only be used if paying by deposit account.



*Vivien Y. Tsang*  
Signature

Dated: March 15, 2004

Vivien Y. Tsang, Esq.  
The Sherwin-Williams Company  
11 Midland Bldg. - Legal Dept.  
101 Prospect Avenue, N.W.  
Cleveland, Ohio 44115

Reg. No. 40,209  
Phone: (216) 566-2487

CC:

<b>CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)</b>			Docket No.
Applicant(s): Thomas J. Staunton & Weilin Tang			7455
Serial No.	Filing Date	Examiner	Group Art Unit
10/701,858	11/05/2003		1713
Invention: CURABLE COMPOSITIONS			
			
I hereby certify that the following correspondence:			
<div>a Preliminary Amendment, along with a Transmittal of Information Disclosure Statement (Under 37 CFR 1.97(b) or (c)) (in duplicate), an Information Disclosure Statement, Information Disclosure Citation - Form PTO-1449, and references</div>			
(Identify type of correspondence)			
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on			
<div>March 15, 2004</div> <div>(Date)</div>			
<div>Laurie M. Feltes</div> <div>(Typed or Printed Name of Person Mailing Correspondence)</div>			
<div></div> <div>(Signature of Person Mailing Correspondence)</div>			
<div>EV 092005505</div> <div>("Express Mail" Mailing Label Number)</div>			
Note: Each paper must have its own certificate of mailing.			



Practitioner's Docket No. 7455

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Patent application

of \_\_\_\_\_  
Inventor(s)

for \_\_\_\_\_  
Title of invention

the specification of which is being transmitted herewith

OR

In re application of: Thomas J. Staunton & Weilin Tang

Application No.: 0 10/ 701,858 Group No.: 1713

Filed: 11/05/2003 Examiner:

For: CURABLE COMPOSITIONS

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

**CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10\***

*(When using Express Mail, the Express Mail label number is mandatory;  
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

37 C.F.R. § 1.8(a)

☐ with sufficient postage as first class mail.

37 C.F.R. § 1.10\*

☒ as "Express Mail Post Office to Addressee"

Mailing Label No. EV 092005505 US  
(mandatory.)

**TRANSMISSION**

☐ transmitted by facsimile to the Patent and Trademark Office.

Laurie M. Feltes  
Signature

Date: March 15, 2004

Laurie M. Feltes

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by Express Mail **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. § 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996. 60 Fed. Reg. 56,439, at 56,442.

(Information Disclosure Statement [6-1]—page 1 of 4)

NOTE: "An information disclosure statement shall be considered by the Office if filed by the applicant:

- (1) Within three months of the filing date of a national application;
  - (2) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; or
  - (3) Before the mailing date of a first Office action on the merits, whichever event occurs last."
- 37 C.F.R. § 1.97(b).

NOTE: "Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section." 37 C.F.R. § 1.56(a).

"Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) each inventor named in the application;
- (2) each attorney or agent who prepares or prosecutes the application; and
- (3) every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application." 37 C.F.R. § 1.56(c).

NOTE: The "duty as described in § 1.56 will be met so long as the information in question was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98 before issuance of the patent." Notice of January 9, 1992, 1135 O.G. 13 -25 at 17.

WARNING: "No information disclosure statement may be filed in a provisional application." 37 C.F.R. § 1.51(b).

### List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

(check sections forming a part of this statement: discard unused sections and number pages consecutively)

1. ☒ Preliminary Statements
2. ☒ FORMS PTO/SB/08A and 08B (formerly FORM PTO-1449)
3. ☐ Statement as to Information Not Found in Patents or Publications
4. ☐ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted
5. ☐ Cumulative Patents or Publications
6. ☒ Copies of Listed Information Items Accompanying This Statement
7. ☐ Concise Explanation of Non-English Language Listed Information Items
  - 7A. ☐ EPO Search Report
  - 7B. ☐ English Language Version of EPO Search Report
8. ☐ Translation(s) of Non-English Language Documents
9. ☐ Concise Explanation of English Language Listed Information Items (Optional)
10. ☐ Identification of Person(s) Making This Information Disclosure Statement

(complete the following, if appropriate)

Sections

, respectively, have been continued on ADDED PAGE(S).

NOTE: "Once the minimum requirements are met, the examiner has an obligation to consider the information." Notice of April 20, 1992 (1138 O.G. 37-41, 37).

## **Section 1. Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Section 10. Identification of Person(s) Making This Information Disclosure Statement**

The person making this statement is

*(check each applicable item)*

- (a) ☐ the inventor(s) who signs below

\_\_\_\_\_  
SIGNATURE OF INVENTOR

\_\_\_\_\_  
*(type name of inventor who is signing)*

- (b) ☐ an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c))


\_\_\_\_\_  
SIGNATURE OF INVENTOR

\_\_\_\_\_  
*(type name of inventor who is signing)*

- (c) ☐ the practitioner who signs below on the basis of the information:

*(check each applicable item)*

- ☐ supplied by the inventor(s).  
☐ supplied by an individual associated with the filing and prosecution of this application. (37 C.F.R. § 1.56(c))  
☐ in the practitioner's file.

  
\_\_\_\_\_  
SIGNATURE OF PRACTITIONER

Vivien Y. Tsang

\_\_\_\_\_  
*(type or print name of practitioner)*

The Sherwin-Williams Company

P.O. Address

11 Midland Bldg. - Legal Dept.  
101 Prospect Avenue, N.W.

Cleveland, Ohio 44115

Reg. No.: 40,209

Tel. No.: (216) 566-2487

Customer No.:

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 7455		SERIAL NO. 10/701,858	
				APPLICANT(S) Thomas J. Staunton & Weilin Tang			
				FILING DATE 11/05/2003		GROUP 1713	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	3,808,162	04/30/1974	Allen et al.	260	18 TN	10/10/1972	
	4,019,933	04/26/1977	Cuksee et al.	149	19.4	07/27/1973	
	4,096,128	06/20/1978	Frisch et al.	260	77.5 SS	03/03/1977	
	4,184,031	01/15/1980	Graham et al.	528	55	10/11/1977	
	4,341,689	07/27/1982	Doshi et al.	523	211	07/02/1981	
	4,426,510	01/17/1984	DelDonno	528	49	08/05/1982	
	4,235,766	11/25/1980	Kuijper	260	33.4 UR	09/15/1978	
	4,251,427	02/17/1981	Recker et al.	260	37 N	09/18/1979	
	4,732,957	03/22/1988	Schuster et al.	528	58	03/17/1986	
	4,877,829	10/31/1989	Vu et al.	524	729	05/19/1988	
	4,902,378	02/20/1990	Ouderkirk et al.	156	643	04/27/1988	

FOREIGN PATENT DOCUMENTS								
*	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
*	EXAMINER INITIAL	DOCUMENT NUMBER	

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>	ATTY DOCKET NO. <b>7455</b>	SERIAL NO. <b>10/701,858</b>
	APPLICANT(S) <b>Thomas J. Staunton &amp; Weilin Tang</b>	
	FILING DATE <b>11/05/2003</b>	GROUP <b>1713</b>

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,110,843	05/05/1992	Bries et al.	521	159	05/01/1991
	5,157,100	10/20/1992	Babjak et al.	528	73	09/20/1991
	5,177,117	01/05/1993	Coe et al.	521	117	03/23/1990
	6,469,122 B1	10/22/2002	Asahina et al.	528	59	04/08/1999
	6,472,493 B1	10/29/2002	Huynh-Ba	528	49	11/23/1999

**FOREIGN PATENT DOCUMENTS**

*	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*


<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.